Emergent BiosolutionsEBS
EBS
About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Employees: 1,600
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
116% more call options, than puts
Call options by funds: $4.86M | Put options by funds: $2.25M
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
26% more capital invested
Capital invested by funds: $265M [Q3] → $332M (+$67.5M) [Q4]
11% more funds holding
Funds holding: 140 [Q3] → 156 (+16) [Q4]
5.46% more ownership
Funds ownership: 58.66% [Q3] → 64.12% (+5.46%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
190%
upside
Avg. target
$15
190%
upside
High target
$15
190%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 24 / 54 met price target | 190%upside $15 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 11 articles about EBS published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Emergent BioSolutions Announces Stock Repurchase Program
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026.
Neutral
GlobeNewsWire
1 week ago
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan").
Neutral
GlobeNewsWire
1 week ago
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada
Neutral
GlobeNewsWire
2 weeks ago
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments.
Neutral
GlobeNewsWire
2 weeks ago
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio.
Neutral
GlobeNewsWire
2 weeks ago
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread opioid emergency preparedness as opioid overdose death rates continue to decline nationwide for the first time in five years.1 These efforts include working with organizations to expand access to NARCAN® Nasal Spray and educate the public on how to respond to an opioid overdose emergency.
Neutral
GlobeNewsWire
3 weeks ago
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland's next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies, today announced entry into an agreement for Emergent's strategic financial investment into Swiss Rockets Ltd, the parent company of Rocketvax Ltd, to support research, infrastructure development, and the expansion of Swiss Rockets' innovative biotechnology portfolio. This endeavor underscores Emergent's commitment to supporting Swiss Rockets' broader mission of pioneering breakthrough medical technologies.
Neutral
GlobeNewsWire
3 weeks ago
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
Neutral
Seeking Alpha
4 weeks ago
Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Officer Richard Lindahl - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Nick Richitt - JPMorgan Brandon Folkes - Rodman & Renshaw Operator Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. Fourth Quarter 2024 Earnings Conference Call.
Positive
Zacks Investment Research
4 weeks ago
Emergent Biosolutions (EBS) Q4 Earnings Top Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.
Charts implemented using Lightweight Charts™